NCT05313854

Brief Summary

This prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 16, 2022

Completed
21 days until next milestone

First Posted

Study publicly available on registry

April 6, 2022

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

April 6, 2022

Status Verified

March 1, 2022

Enrollment Period

3 years

First QC Date

March 16, 2022

Last Update Submit

March 29, 2022

Conditions

Pancreatic Cancer

Keywords

Pancreatic CancerMachine LearningRadiomicsCTMRIUltrasound

Outcome Measures

Primary Outcomes (1)

  • Patient overall survival

    Patient overall survival, from the time of diagnosis of pancreatic tumor to the death of the patient.

    up to 3 years

Secondary Outcomes (1)

  • Pathology diagnosis

    intraoperative

Other Outcomes (1)

  • Progression-free Survival

    up to 3 years

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

hospitalized patients with radiology conformed pancreatic tumor

You may qualify if:

  • Clinical diagnosis of pancreatic tumor; Must have CT / MRI / ultrasound data and pathology diagnosis

You may not qualify if:

  • Have other tumors along with pancreatic tumor; Clinical information missing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, China

RECRUITING

Related Publications (1)

  • Xu X, Qu J, Zhang Y, Qian X, Chen T, Liu Y. Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma. Front Oncol. 2023 Feb 24;13:1074445. doi: 10.3389/fonc.2023.1074445. eCollection 2023.

    PMID: 36910599DERIVED

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Tao Chen, Dr

    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Xinsen Xu, Dr

CONTACT

+86-21-68383713xuxinsen@gmail.com

Tao Chen, Dr

CONTACT

+86-21-68383713dr_chentao78@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2022

First Posted

April 6, 2022

Study Start

January 1, 2021

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

April 6, 2022

Record last verified: 2022-03

Locations

CN(1)